Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
A biomarker to predict future response to ixekizumab therapy was investigated in a single phase 2 study and has not been replicated. This experiment evaluated the correlation between baseline mRNA expression of TRGV and clinical response to ixekizumab in patients with chronic moderate-to-severe plaque psoriasis. 1
There are no current commercial assays that test for TRGV levels, and there are no standards that would define high levels of TRGV.1
Phase 3 clinical trials
Lilly has not tested biomarkers in phase 3 studies.
1. Krueger JG., Suarez-Farinas M, Beselin A, et al. Baseline expression of T cell receptor gamma-V gene family is associated with high levels of response to ixekizumab treatment in psoriasis. J Invest Dermatol 2015; 135: S32-S32. http://www.jidonline.org/article/S0022-202X(15)60202-0/pdf
Glossary
Lilly = Eli Lilly and Company
TRGV = T cell receptor gamma-V
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2019 M03 04